Arctic Bioscience reports positive Q3 2025 results amid clinical and financial progress

Arctic Bioscience announced statistically significant effects of HRO350 on systemic inflammation in its HeROPA study for mild-to-moderate psoriasis, a key highlight of Q3 2025. HRO350 treatment led to a ≥25% reduction in systemic inflammatory markers over 26 weeks and one year compared to placebo. Additionally, a clinical study published in International Ophthalmology confirmed ROMEGA® herring roe oil improved visual field in glaucoma patients with no adverse effects. These findings are crucial for commercial dialogues with potential partners, as chief executive Christer Valderhaug noted.

The company's nutraceutical segment saw sales revenues of NOK 8.7 million in Q3 2025, with year-to-date sales at NOK 25.9 million, slightly down from last year due to a resolved recall issue. Strong order intake for 2026, especially from the American market and new customers, indicates positive future growth. Arctic Algae secured a NOK 2.5 million grant for an aquaculture vaccine project, underscoring ongoing R&D efforts.

Cost-reduction initiatives positively impacted Q3 adjusted EBITDA, which improved to NOK -7.8 million from NOK -8.4 million year-over-year. Overall operational costs year-to-date are NOK 8.9 million lower than in 2024. The company's liquidity stood at NOK 7.5 million at the end of Q3 2025, and discussions with its main bank connection are ongoing to strengthen its financial position.